durvalumab + tremelimumab + oxaliplatin + 5-fluorouracil + leucovorin

A combination regimen consisting of **durvalumab** (a monoclonal antibody targeting the programmed death-ligand 1, PD-L1), **tremelimumab** (a monoclonal antibody targeting cytotoxic T-lymphocyte-associated protein 4, CTLA-4), **oxaliplatin** (a platinum-based chemotherapeutic agent that induces DNA crosslinking), **5-fluorouracil** (a pyrimidine analog that inhibits thymidylate synthase, disrupting DNA synthesis), and **leucovorin** (a reduced folate used to enhance the efficacy of 5-fluorouracil). This combination has been evaluated as a first-line regimen for metastatic or advanced colorectal cancer, particularly microsatellite stable (MSS) disease. Durvalumab and tremelimumab provide checkpoint inhibition (immunotherapy), while oxaliplatin, 5-fluorouracil, and leucovorin comprise the mFOLFOX6 chemotherapy backbone[6].

Brand names

ImfinziImjudo

Other names

durvalumab + tremelimumab + oxaliplatin + 5-fluorouracil + leucovorindurvalumab + tremelimumab + mFOLFOX6